

CSF Biomarkers in Alzheimer's Disease (AD), a descriptive classification scheme (A/T/N):

	CSF cut-off values*	CSF ATN classification	ATN** classification presence of:
Aβ Ratio Aβ1-42 /Aβ1-40	>0,069 pg/ml	Pathological if lower --> A+	Amyloid decrease in CSF A β ratio or A β 1-42 in absence of A β 1-40 (Or presence in amyloid PET)
Aβ1-42	>600 pg/ml	priority is ratio over single measured value A β 1-42	
P-Tau181	< 56,5 pg/ml	Pathological if higher -->. T+	Tangles increase in CSF P-Tau181
T-Tau	<404 pg/ml	Pathological if higer -->. N+	Neurodegeneration increase in CSF T-Tau (or presence of atrophy on structural MRI, FDG PET)

*ref. Alcolea et al., 2019 ACTN; cfr.Perugia data, Lumipulse cut-off values

** ref. Jack et al., 2016 Neurology

Summary of consensus comments for interpretation of biochemical profiles of Alzheimer's disease (AD) biomarkers in CSF

A	T	N	<i>consensus comment on CSF biochemical profile</i>
+	+	+	consistent with AD
+	+	-	atypical, consistent with AD
+	-	+	atypical, may be consistent with AD
+	-	-	consistent with an amyloidopathy
-	-	-	not consistent with AD
-	+	+	atypical, not consistent with AD
-	+	-	atypical, not consistent with AD
-	-	+	not consistent with AD, may be consistent with other neurodegenerative disease and/or neural damage; the profile may indicate Creutzfeldt-Jakob (CJD) disease if t-tau is close to/above upper limit of detection with high t-tau/p-tau ratio. A PrP ^{sc} RT-QuIC analyses (ddCJD) will be performed if relevant.

*** ref. Jack et al., 2018 Alzheimers Dement; Delaby et al., 2021 Alzheimers Dement